A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Four deaths cast doubt on J&J’s multi-pronged KLK2 push.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.